• Reference Citation Analysis
  • v
  • v
  • Find an Article
  • Find an Author
Download
Number Citation Analysis
1
Lopez PG, Girard N, Cho B, Sabari J, Spira A, Sanborn R, Goto K, Yang JH, Curtin J, Lyu X, He A, Penton J, Edwards J, Massin GL, Xia K, Chioda M, Thayu M, Knoblauch R, Mahadevia P, Leighl N. 30 Long-term efficacy, safety, and predictors of response to amivantamab among patients with post-platinum EGFR Ex20ins-mutated advanced NSCLC. J Thorac Oncol 2023. [DOI: 10.1016/s1556-0864(23)00257-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/03/2023]
2
Girard N, Besse B, Bernabé Caro R, Goto K, Leighl N, Ohe Y, Sabari J, Lee SH, Lin X, Schaeffer M, Nair S, Li T, Di Scala L, Potluri R, Mahadevia P, Thayu M, Kim T. EP08.02-016 Frontline and Post-Osimertinib Therapy for EGFR-mutant Advanced NSCLC: Treatment Patterns, Outcomes, Healthcare Use and Costs. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.698] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
3
Marmarelis M, Lee SH, Spira A, Ou SH, Waqar S, Li S, Thayu M, Knoblauch R, Bauml J, Cho B. MA07.04 Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy in Relapsed/Refractory EGFR-mutant NSCLC. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.114] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
4
Cho B, Lee SH, Han JY, Cho E, Lee JS, Lee K, Curtin J, Gao G, Xie J, Schnepp R, Bauml J, Knoblauch R, Thayu M, Kim DW. P1.16-01 Amivantamab and Lazertinib in Treatment-Naive EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC). J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.210] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
5
Trigo J, Cho B, Park K, Girard N, Viteri S, Garrido P, Krebs M, Thayu M, Knoblauch R, Xie J, Bauml J, Schnepp R, Londhe A, Mahadevia P, Leighl N. 20P Risk and management of intracranial progression on amivantamab in epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins)-mutated non-small cell lung cancer (NSCLC). Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.02.029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022]  Open
6
Leighl N, Shu C, Minchom A, Felip E, Cousin S, Cho B, Park K, Han JY, Boyer M, Lee C, Garcia VM, Tomasini P, Viteri S, Xie J, Mertz J, Artis E, Schnepp R, Knoblauch R, Thayu M, Perez JT. 1192MO Amivantamab monotherapy and in combination with lazertinib in post-osimertinib EGFR-mutant NSCLC: Analysis from the CHRYSALIS study. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1797] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]  Open
7
Shu C, Goto K, Ohe Y, Besse B, Park K, Wang Y, Griesinger F, Yang JH, Felip E, Sanborn R, Caro RB, Bauml J, Chen J, Fennema E, Mahoney J, Trani L, Knoblauch R, Thayu M, Cho B. 1193MO Amivantamab plus lazertinib in post-osimertinib, post-platinum chemotherapy EGFR-mutant non-small cell lung cancer (NSCLC): Preliminary results from CHRYSALIS-2. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1798] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]  Open
8
Park K, Sabari J, Haura E, Shu C, Spira A, Salgia R, Reckamp K, Sanborn R, Govindan R, Bauml J, Curtin J, Xie J, Roshak A, Lorenzini P, Millington D, Thayu M, Knoblauch R, Cho B. 1247P Management of infusion-related reactions (IRRs) in patients receiving amivantamab. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1852] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]  Open
9
Sabari J, Shu C, Park K, Leighl N, Mitchell P, Kim S, Lee J, Kim D, Viteri S, Spira A, Han J, Trigo J, Lee C, Lee K, Girard N, Yang T, Goto K, Sanborn R, Yang J, Xie J, Roshak A, Thayu M, Knoblauch R, Cho B. OA04.04 Amivantamab in Post-platinum EGFR Exon 20 Insertion Mutant Non-small Cell Lung Cancer. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.284] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
10
Cho B, Lee K, Cho E, Kim DW, Lee JS, Han JY, Kim SW, Spira A, Haura E, Sabari J, Sanborn R, Bauml J, Gomez J, Lorenzini P, Infante J, Xie J, Haddish-Berhane N, Thayu M, Knoblauch R, Park K. 1258O Amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in combination with lazertinib, a 3rd-generation tyrosine kinase inhibitor (TKI), in advanced EGFR NSCLC. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1572] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]  Open
11
Yun J, Kang H, Lee S, Park C, Jeong S, Hong M, Kim H, Thayu M, Curtin J, Knoblauch R, Lorenzi M, Roshak A, Cho B. P1.01-94 JNJ-61186372, an EGFR-cMet Bispecific Antibody, in EGFR Exon 20 Insertion-Driven Advanced NSCLC. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.809] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
12
Pillai R, Ramalingam S, Paz-Ares L, Thayu M, Watson P, Reck M. P3.04-008 A Phase 1b/2 Study of Atezolizumab With or Without Daratumumab in Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC). J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.1666] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
13
Thayu M, Baltimore RS, Sleight BJ, Reyes-Mugica M, Hotez PJ. CDC group IV c-2 bacteremia in a child with recurrent acute monoblastic leukemia. Pediatr Infect Dis J 1999;18:397-8. [PMID: 10223705 DOI: 10.1097/00006454-199904000-00025] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
14
Thayu M, Tallini G, Glusac EJ, Kacinski BM, Wilson LD. Evaluation of T-cell receptor gene rearrangements in patients with recurrent patch/plaque (T2) CTCL (mycosis fungoides). Yale J Biol Med 1999;72:365-75. [PMID: 11138932 PMCID: PMC2579043] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
PrevPage 1 of 1 1Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA